Dexcom Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Dexcom Inc in the second quarter 2026?
Dexcom Inc achieved a return on average equity (ROE) of 36.25 % in its second quarter 2026, this is above DXCM's average return on equity of -5.87%.
Dexcom Inc s equity during the 12 months ending in the second quarter 2026 are valued at $2 billion

ROE has advanced compared to 33.83% in the first quarter 2026, due to net income growth.

Within the Medical Equipment & Supplies industry 6 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 326, from total ROE ranking in the first quarter 2026 at 333.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	1.88 %	30.46 %	30.6 %	37.75 %	-
Y / Y Net Income Change	39.49 %	89.28 %	76.2 %	110.85 %	25.3 %
Net Income (TTM) in Millions	1,001	930	836	721	572
Return On Equity (TTM)	36.25 %	33.83 %	32.44 %	29.82 %	25.62 %
DXCM's Total Ranking	# 326	# 333	# 99	# 302	# 386
Equity (TTM) in Millions	2,621	2,957	2,746	2,726	2,573
Seq. Equity Change	-11.35 %	7.68 %	0.73 %	5.95 %	13.52 %
Seq. Net Income Change	25.71 %	-25.36 %	-5.81 %	57.84 %	70.59 %

Back to DXCM Management Effectiveness >> DXCM's 5 Years Annual ROE >> Compare DXCM ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 7
Sector	# 50
Overall	# 326

Return On Equity Statistics
High	Average	Low
36.98 %	-5.87 %	-64.01 %
(Dec 31 2020)		(Mar 31 2013)

DXCM Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	2,746	2,103	2,069	2,132	2,252
Y / Y Equity Change	30.6 %	1.64 %	-2.96 %	-5.32 %	23.27 %
Net Income in Millions	836	576	542	341	155
Y / Y Net Income Change	45.14 %	6.41 %	58.7 %	120.56 %	-68.66 %
Return On Equity	30.46 %	27.4 %	26.18 %	16.01 %	6.87 %

Back to DXCM Management Effectiveness >> DXCM's 5 Years Annual ROE >> Compare DXCM ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 30.46 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
DXCM's' Return on Equity at Yahoo Finance
DXCM's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for DXCM's Competitors
Subscribers only: Roe for Dexcom Inc 's Suppliers
Subscribers only: Return On Equity for DXCM's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Rigel Pharmaceuticals Inc	96.49 %
Exelixis Inc	93.62 %
Alnylam Pharmaceuticals Inc	93.61 %
Eli Lilly And Company	92.54 %
Amgen Inc	89.32 %
Q32 Bio Inc	76.88 %
3m Company	76.55 %
Oramed Pharmaceuticals Inc	73.03 %
Tg Therapeutics Inc	72.30 %
Idexx Laboratories Inc	71.96 %
Elite Pharmaceuticals Inc	71.10 %
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %
Concentra Group Holdings Parent Inc	48.13 %
Bristol myers Squibb Company	46.65 %
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %

Date modified: 2026-09-14T03:52:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.